ArticleNPJ precision oncology2026

SGI-7079 as a novel type I FLT3 inhibitor overcomes resistance to gilteritinib and quizartinib mediated by ITD and TKD mutations in acute myeloid leukemia.

Zhiwei Zhong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.